drugset / Trial / NCT05165394
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
Timeline
- Start
- 2021-11-30
- Primary completion
- 2023-07-07
- Completion
- 2023-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZELATRIAZIN | Small molecule | — | Oral |